Canada Pension Plan Investment Board Has $106,000 Stake in Bruker Co. (NASDAQ:BRKR)

Canada Pension Plan Investment Board lowered its holdings in Bruker Co. (NASDAQ:BRKR) by 50.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,800 shares of the medical research company’s stock after selling 1,800 shares during the period. Canada Pension Plan Investment Board’s holdings in Bruker were worth $106,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. FIL Ltd grew its position in Bruker by 262.3% during the fourth quarter. FIL Ltd now owns 1,961,416 shares of the medical research company’s stock worth $114,978,000 after buying an additional 1,420,102 shares in the last quarter. Norges Bank acquired a new stake in shares of Bruker during the 4th quarter worth $63,378,000. Marshall Wace LLP increased its position in shares of Bruker by 4,510.3% in the fourth quarter. Marshall Wace LLP now owns 783,988 shares of the medical research company’s stock worth $45,957,000 after purchasing an additional 766,983 shares during the period. Vaughan Nelson Investment Management L.P. raised its stake in Bruker by 140.3% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 1,141,762 shares of the medical research company’s stock valued at $66,930,000 after purchasing an additional 666,617 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Bruker by 139.3% during the fourth quarter. JPMorgan Chase & Co. now owns 526,166 shares of the medical research company’s stock worth $30,844,000 after purchasing an additional 306,282 shares during the period. 79.52% of the stock is owned by institutional investors.

Bruker Stock Performance

NASDAQ:BRKR opened at $39.07 on Friday. The stock’s 50-day moving average is $43.22 and its 200-day moving average is $52.70. The stock has a market cap of $5.92 billion, a P/E ratio of 51.41, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. Bruker Co. has a 1-year low of $34.10 and a 1-year high of $82.04. The company has a current ratio of 1.60, a quick ratio of 0.77 and a debt-to-equity ratio of 1.15.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. Equities research analysts anticipate that Bruker Co. will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Monday, March 17th were given a $0.05 dividend. The ex-dividend date of this dividend was Monday, March 17th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.51%. Bruker’s dividend payout ratio (DPR) is presently 26.32%.

Wall Street Analysts Forecast Growth

BRKR has been the subject of several analyst reports. Wells Fargo & Company dropped their target price on shares of Bruker from $75.00 to $60.00 and set an “overweight” rating for the company in a research report on Thursday, April 17th. Barclays lowered their price objective on shares of Bruker from $60.00 to $50.00 and set an “overweight” rating for the company in a research report on Thursday, April 10th. Guggenheim reaffirmed a “buy” rating on shares of Bruker in a report on Monday, February 24th. Citigroup lowered their price target on Bruker from $75.00 to $50.00 and set a “buy” rating for the company in a report on Monday, April 7th. Finally, Stifel Nicolaus decreased their target price on Bruker from $70.00 to $57.00 and set a “hold” rating on the stock in a research report on Friday, February 14th. Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $65.00.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.